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Ergosterol is the yeast functional equivalent of cholesterol in mammalian cells. Deletion of the ERG6 gene, which encodes an enzyme
catalyzing a late step of ergosterol biosynthesis, impedes targeting of the tryptophan permease Tat2p to the plasma membrane, but does not
promote vacuolar degradation. It is unknown whether similar features appear when other steps of ergosterol biogenesis are inhibited. We show
herein that the ergosterol biosynthesis inhibitor zaragozic acid (ZA) evoked massive vacuolar degradation of Tat2p, accompanied by a decrease in
tryptophan uptake. ZA inhibits squalene synthetase (SQS, EC 2.5.1.21), which catalyzes the first committed step in the formation of cholesterol/
ergosterol. The degradation of Tat2p was dependent on the Rsp5p-mediated ubiquitination of Tat2p and was not suppressed by deletions of VPS1,
VPS27, VPS45 or PEP12. We will discuss ZA-mediated Tat2p degradation in the context of lipid rafts.
© 2007 Published by Elsevier B.V.Keywords: Ergosterol; Zaragozic acid; Rapamycin; Tryptophan; Tat2p1. Introduction
In the budding yeast Saccharomyces cerevisiae, the tryp-
tophan permease Tat2p is synthesized in the endoplasmic
reticulum (ER) and trafficked via the secretory pathway to
the plasma membrane [1–3]. However, proteolytic degradation
of Tat2p in the vacuole is evoked in response to various
environmental conditions, including nutrient starvation, high
tryptophan, and high pressure stress [1–5]. Especially, Tat2p
degradation and a resultant decrease in tryptophan uptake
activity become the Achilles' heel of yeast growth under high-
pressure stress conditions [4]. This vacuolar targeting is
dependent on the ubiquitination of Tat2p.
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doi:10.1016/j.bbamem.2007.03.022number of enzymes encoded by ERG genes in yeast (see Fig.
1). Yeast mutants with deletion of ERG6, which encodes an
enzyme required for a late step of ergosterol biogenesis, are
defective in tryptophan uptake [6]. The ERG6-deleted strain
cells are viable in a tryptophan autotrophic (TRP1), but not
auxotrophic (trp1), background and the lethality of the erg6
trp1 cells is suppressed by addition of high concentrations of
tryptophan [2]. These facts indicate that tryptophan uptake is
critical for viability of the erg6 mutant. Interestingly, vacuolar
degradation of Tat2p was not, however, promoted in this mutant
in the presence of sufficient tryptophan, although targeting of
Tat2p to the plasma membrane was compromised [2]. In this
mutant, vacuolar degradation of Tat2p was clearly observed
only when the concentration of tryptophan in the medium was
low [2]. It is unknown whether similar features would appear if
other steps of ergosterol biogenesis were inhibited.
Squalene synthetase (SQS, EC 2.5.1.21), encoded by ERG9
in yeast, catalyzes the conversion of farnesyl pyrophosphate to
squalene (Fig. 1). This reaction represents the first committed
step in the formation of cholesterol and related sterols and is
thought to represent a major control point of isoprene and sterol
Fig. 1. Sterol synthesis pathway and inhibitors in yeast.
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zaragozic acid (ZA) acts as a competitive inhibitor of SQS. It
is likely that erg6-deleted mutants can grow by producing
zymosterol (see Fig. 1), whereas erg9 mutations (or inhibition)
are lethal, probably because of the lack of such sterols. Here we
show that ZA promoted vacuolar degradation of Tat2p, unlike
erg6 mutation. ZA-stimulated vacuolar targeting of Tat2p was
mediated by ubiquitination.2. Materials and methods
2.1. Strains, plasmids, and media
For experiments with sterol inhibitors, wild-type strain KMY1005 (SCU7;
MATα leu2-3,112 ura3-52 his3Δ200 trp1Δ901 lys2-801) [12] and its derivatives
SCU645 (pep4::loxP-kanMX4-loxP), SCU757 (vps45::hphMX4), SCU718
(vps1:: loxP-kanMX4-loxP), SCU874 (vps27:: loxP-kanMX4-loxP), SCU620
(end4::loxP-kanMX4-loxP), SCU755 (pep12::hphMX) and SCU649 (rsp5::
loxP-kanMX4-loxP [YCp-rsp5-1]) were used. Deletions of PEP4, VPS45, VPS1,
VPS27, PEP12, RSP5 and END4were done by the one-step PCR-mediated gene
disruption method [13–15]. To examine the effect of deletion of ERG6, we used
the wild-type (RH2886; MATα trp1 ade2 ura3 leu2 bar1) and erg6 trp1
(SCU816), which was obtained by mating of erg6Δ (erg6::LEU2; RH3622) [16]
with the trp1 strain (RH2886). Plasmids pRS414 (TRP1 CEN) [17], pHA2-TAT2
(URA3 2 μ), pHA2-TAT2(5KR) (URA3 2 μ) [1, 18] and YCplac33-rsp5-1 (URA3
CEN) [3] were used. The compositions of adenine-containing rich medium
(YPAD) and synthetic minimal medium (SD) were described previously [18].
Normal SD medium contained 20 μg/ml of tryptophan.
2.2. Western blot analysis
Cells (a 25-ml culture in SD grown to mid-log phase) expressing HA2-TAT2
or HA2-TAT2(5KR) were disrupted in 200 μl of lysis buffer (50 mM Tris–HCl,
pH 7.5, 100 mM NaCl, 1 mM EDTA and 1% NP-40) by vortexing 4×30 s withglass beads, using a FastPrep machine (Savant Instruments). The lysis buffer
contained a protease inhibitor cocktail (Complete™, Roche) and protein
phosphatase inhibitors (10 mM NaF, 10 mM p-nitrophenylphosphate, 10 mM
sodium pyrophosphate and 10 mM β-glycerolphosphate). Crude extracts were
cleared with a 5-min, 1500 g, spin and the supernatant was used for Western blot
analysis as previously described [1], using a mouse monoclonal anti-HA antibody
(16B12, BAbCo), a rabbit polyclonal anti-Cdk antibody (for cyclin-dependent
kinase; PSTAIRE, Santa Cruz), and a mouse monoclonal anti-3-phosphoglycerate
kinase antibody (22C5, Molecular Probes).
2.3. Indirect immunofluorescence
Logarithmically growing cells were fixed for 2 h in growth medium
supplemented with formaldehyde (3.7%) and potassium phosphate buffer
(100 mM, pH 6.5). The cells were washed and resuspended in sorbitol buffer
(1.2 M sorbitol, 100 mM potassium phosphate, pH 6.5). The cell walls were
digested for 60–120 min at 37 °C in sorbitol buffer supplemented with 2-
mercaptoethanol (20 mM) and Zymolyase 20T (0.1 mg/ml; Seigagaku Corp).
Spheroplasts were attached to poly-L-lysine-coated glass slides and permeabilized
in PBT (53 mM Na2HPO4, 13 mM NaH2PO4, 75 mM NaCl, 0.1% Triton X-100).
HA-tagged Tat2p was detected with a mouse monoclonal anti-HA antibody (clone
16B12; BAbCO) at a final dilution of 1:500. The samples were treated with
primary antibody for 2 h and subsequently with Cy3-conjugated secondary
antibody (Molecular Probes, Inc.) at a final dilution of 1:500 for 90 min and 4′,6-
diamidino-2-phenylindole (DAPI) for 15 min as described [1]. Washed cells were
viewed using an Olympus IX71-23FL/S microscope (100× objective) and a cooled
charge-couple device camera (ORCA-ER-1, Hamamatsu Photonics) connected to
a Scanalytics Image Processor LuminaVision (Mitani Corp., Tokyo, USA). For
double staining of HA-Tat2p and Pep12p, a rabbit polyclonal anti-HA antibody
(Y11; Santa Cruz) at a final dilution of 1:500 and a mouse monoclonal anti-Pep12
antibody (Molecular Probes, Inc.) at a final dilution of 1:50 were used. After
washing with PBS, cells were treated with Cy3-conjugated anti-rabbit and Alexia
488-conjugated anti-mouse antibodies (Molecular Probes, Inc.) at final dilutions of
1:500. For double staining of HA-Tat2p and alkaline phosphatase (ALP), a rabbit
polyclonal anti-HA antibody (Y11; Santa Cruz) at a final dilution of 1:500 and a
mouse monoclonal anti-ALP antibody (Molecular Probes, Inc.) at a final dilution
of 1:500 were used. After washing with PBS, cells were treated with Cy3-
conjugated anti-mouse and Alexia 488-conjugated anti-rabbit antibodies (Mole-
cular Probes, Inc.) at final dilutions of 1:500.
2.4. Tryptophan import activity
Tryptophan import activity of cells was measured as described [19]. Briefly,
cells (a 5-ml culture in SD grown to mid-log phase) were collected by
centrifugation and washed with 5 ml of SD minus amino acids and finally
resuspended in 500 μl of SD minus amino acids. The assay was initiated by the
addition of 14C-radiolabeled tryptophan to a final concentration of 4 μM. One
hundred-microliter samples were taken at five 1-min intervals and were chilled
by the addition of 900 μl of ice-cold SD minus amino acids. The cells were
collected by filtration through a nitrocellulose filter (pore size 0.45 μm;
Millipore) and washed with 30 ml of chilled water. The filter was dried, and the
amount of intracellular labeled tryptophan was estimated by liquid scintillation
counting. Experiments were repeated with essentially identical results. Only one
set of data is shown here.
2.5. Drug treatments
Stock solutions (at 1000 times the final concentration used) of sterol
synthesis inhibitors, zaragozic acid A (ZA; a kind gift from Merck), terbinafine
(a kind gift from Novartis), and ketoconazole (ICN) were prepared in water,
ethanol, and dimethyl sulfoxide, respectively [20]. Cells were treated with these
drugs at the following concentrations: ZA, 10 μg/ml; terbinafine, 50 μg/ml; or
ketoconazole, 10 μg/ml [20]. Tests of drug susceptibilities of yeast cells were
conducted using cells logarithmically grown in SD medium. Cells were
suspended in YPD medium to a concentration of 6×106 cells per ml (optical
density at 600 nm of 0.2). Cells were plated by transferring 1 μl of the original
suspension (100) plus 10−1 and 10−2 dilutions onto YPD plates containing the
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growth. Stock solutions (at 250 times the final concentration used) of the TOR
inhibitor rapamycin (Wako, Tokyo) were prepared in 90% ethanol and 10%
Tween 20 [1]. Cells were treated with rapamycin at 200 ng/ml.3. Results and discussion
3.1. ZA compromises Tat2p maintenance and tryptophan
uptake
Several kinds of stress induce vacuolar degradation of Tat2p,
whereas inhibition of ergosterol biogenesis by the deletion of
ERG6 only impedes plasma membrane trafficking of Tat2p
without promoting its vacuolar degradation under high try-
ptophan conditions (see Introduction). In another line of our
study, we also found that erg6 deletion did not cause Tat2p
degradation under normal tryptophan conditions (Fig. 2C).Fig. 2. Reduction of Tat2p protein and tryptophan uptake by inhibitors of sterol biosy
type strain (SCU7) cells and cells transformed with plasmid pRS414 (TRP1 CEN). S
containing each drug: zaragozic acid (ZA; 10 μg/ml), terbinafine (50 μg/ml), or keto
Tat2p protein by ergosterol synthesis inhibitors. The wild-type strain (KMY1005)
terbinafine (50 μg/ml), or ketoconazole (10 μg/ml) for 3 h, and the protein levels o
examined by Western blotting using anti-HA and anti-CDK antibodies. (C) Tat2p pro
and CDK in the wild-type (RH2886, lanes 1 and 2) and erg6 (SCU816, lane 3) st
blotting. For the control, we used cells treated with rapamycin (200 ng/ml) for 1 h (la
done as described in panel B. Tryptophan uptake activity was determined as desc
essentially identical results. Only one set of data is shown.Furthermore, the ERG genes encoding enzymes involved in
later steps of ergosterol biosynthesis (ERG6, ERG2, ERG3,
ERG5, and ERG4) (see Fig. 1) are not essential for cell viability,
whereas those involved in earlier steps (ERG9, ERG1, ERG7,
and ERG11) are required for viability. This suggests that defects
in earlier steps of ergosterol biosynthesis may cause different
effects on membrane trafficking of proteins than the defect in
ERG6. We were curious whether this different phenomenon
regarding Tat2p is caused by inhibition of earlier steps of
ergosterol biosynthesis. In this study, we used tryptophan
auxotrophic (trp1), not autotrophic (TRP1), cells, and a standard
concentration (20 μg/ml) of tryptophan in culture media, in
order to be able to compare the results to those of previous
studies [1–5,18,21].
Various inhibitors of enzymes involved in the earlier steps
are available, including ZA (an inhibitor of SQS encoded by
ERG9), terbinafine (an inhibitor of squalene epoxidase encodednthesis. (A) Cell growth inhibition by ergosterol synthesis inhibitors. The wild-
erially diluted cells of each strain were spotted from left to right on YPD plates
conazole (10 μg/ml). Plates were cultured at 30 °C for 2 days. (B) Decrease of
harboring plasmid pHA2-TAT2 (pSCU301) was treated with ZA (10 μg/ml),
f Tat2p (HA2-Tat2), and cyclin-dependent kinase (CDK; loading control) were
tein is not decreased by erg6 disruption. The protein levels of Tat2p (HA-Tat2)
rains harboring plasmid pHA2-TAT2 (pSCU301) were determined by Western
ne 2). (D) Tryptophan uptake declined in the ZA-treated cells. ZA treatment was
ribed in Materials and methods. Independent experiments were repeated with
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demethylase encoded by ERG11) (see Fig. 1). We treated cells
with each drug at the concentration normally used (namely, at
which the agent fully inhibits the activity of the corresponding
enzyme) [20,22–24]. ZA, terbinafine and ketoconazole com-
pletely inhibited cell growth in our strain background. This was
the case regardless of whether the cells were in a TRP1 or trp1
background (Fig. 2A), consistent with the non-viability of cells
deleted for ERG9, ERG1 and ERG11. This is in sharp contrast
to the fact that the erg6 cells are viable in a TRP1, but not trp1,
background [2].
In order to assess whether these inhibitors promoted vacuolar
degradation of Tat2p, as do nutrient starvation, high tryptophan
and high pressure, first we examined the effects of these
inhibitors of ergosterol synthesis on Tat2p protein levels. In
contrast to ERG6 disruption (Fig. 2C), which does not cause a
decrease in cellular Tat2p protein under tryptophan-sufficient
conditions [2], ZA drastically reduced the level of cellular Tat2p
protein even if sufficient tryptophan was provided (Fig. 2B). In
addition, terbinafine decreased the level to a lesser extent. In
contrast, no obvious effect was found in the presence of
ketoconazole. Rapamycin immediately promotes the pathway
of Tat2p degradation [1]. In contrast, we found that Tat2p was
almost lost 3 h after ZA treatment in a preliminary study. This is
probably because ergosterol constituents in the cells gradually
changed. Cells treated with ZA for 3 h did not lose viability,
which was checked by colony formation (data not shown). In
order to assess the effect of ZA on Tat2p clearly, we adopted 3 h
of ZA treatment.
Thus, the activities of enzymes of early steps of ergosterol
biosynthesis, namely, SQS and squalene eposidase, are critical
for Tat2p maintenance, unlike sterol C-24 methyltransferase
encoded by ERG6. Indeed, tryptophan import activity was
decreased by the most potent inhibitor, ZA (Fig. 2D). Some
residual import activity was detected in the ZA-treated cells in
this assay (see below).
3.2. ZA induces vacuolar sorting and degradation of Tat2p
We then focused on further characterizing ZA. Under
normal conditions, the plasma-membrane localization of Tat2p
was not evident and Tat2p showed a punctate intracellular
localization (Fig. 3A). The punctate signals were co-localized
with Pep12, the syntaxin that marks late endosomes (Fig. 3A),
as described previously [1,2]. This demonstrates that Tat2p is
predominantly distributed to late endosomes under normal
tryptophan conditions.
We suspected that Tat2p is targeted to and degraded in the
vacuoles in ZA-treated cells. Tat2p signals were very weak in
most ZA-treated cells (data not shown), consistent with a lowered
level of Tat2p protein (see Fig. 2A). However, Tat2p was found to
be co-localized with the vacuolar membrane protein alkaline
phosphatase (ALP) in some ZA-treated cells (Fig. 3B). This
suggests that ZA promotes vacuolar targeting of Tat2p.
To verify this, we examined the effects of deletion of the
PEP4 gene on the decrease in the protein level of Tat2p
caused by ZA. PEP4 encodes the vacuolar protease respon-sible for the degradation of Tat2p in the vacuole [1,2]. If ZA
promotes the vacuolar degradation of Tat2p, the decrease in
Tat2p ought to be suppressed by deletion of PEP4. This was
indeed the case, as pep4Δ prevented the ZA-induced reduction
of Tat2p (Fig. 3C). Consistent with this, clear vacuolar
accumulation of Tat2p was observed in the pep4 mutants
(Fig. 3D). Thus, ZA elicits missorting and vacuolar degrada-
tion of Tat2p.
3.3. Rsp5p-mediated ubiquitination of Tat2p is required for the
ZA-induced vacuolar missorting of Tat2p
Tat2p vacuolar targeting stimulated by nutrient starvation,
high tryptophan, and high pressure is mediated by ubiquitina-
tion of Tat2p. This is mediated by the ubiquitin ligase Rsp5p
and alleviated by the ubiquitin-specific proteases Doa4p,
Ubp6p and Ubp14p [1–4]. The protein kinase TOR (target
of rapamycin), which is a central controller of cell growth in
response to nutrient availability, controls the vacuolar sorting
of Tat2p: rapamycin, a specific inhibitor of TOR, stimulates
the vacuolar targeting and degradation of Tat2p [1] (see Fig.
1C). Vacuolar sorting is thought to be primed by Tat2p
ubiquitination [1,2], which is prevented by the use of Tat2
(5KR)p, a stabilised version of Tat2p in which five putative
ubiquitination target lysine sites in the NH2-terminus of Tat2p
are substituted by arginine. Tat2(5KR)p is predominantly
localized to the plasma membrane, and its localization and
protein level are resistant to rapamycin. Rapamycin-induced
Tat2p degradation is completely suppressed by these muta-
tions. However, substitution of three of these five lysine
residues by arginine was sufficient for prevention of the
ubiquitination of Tat2p in ERG+ strains, but not the erg6
mutant [1,2].
Tat2(5KR)p was clearly observed on the plasma membrane
(Fig. 4A), as described previously [1]. It was still localized
there even after ZA treatment, in sharp contrast to the wild-
type Tat2p. In addition, this mutation suppressed ZA-induced
Tat2p degradation, as well as rapamycin-induced one (Fig.
4B). Thus, vacuolar missorting of Tat2p in ZA-treated cells is
dependent on its ubiquitination. Furthermore, a conditional
mutation allele of rsp5, rsp5-1, partially suppressed ZA-
induced Tat2p degradation at restrictive temperatures, as well
as the rapamycin-induced degradation (Fig. 4B). Based on all
these findings, we conclude that ZA-induced vacuolar
degradation of Tat2p is dependent on Rsp5p-mediated
ubiquitination of Tat2p.
3.4. Vacuolar sorting pathway of Tat2p in ZA-treated cells
Tat2p is sorted from early endosomes either to plasma
membranes or to late endosomes, and subsequently targeted to
vacuoles [1,2] (see Fig. 8). Rapamycin accelerated sorting of
Tat2p from plasma membranes to vacuoles. However, this
degradation route is a minor pathway, because massive Tat2p
degradation still occurs in the end4 mutant [1]. It is likely that
the massive degradation of Tat2p caused by rapamycin reflects
vacuolar degradation of endosomal Tat2p. Similarly, Tat2p
Fig. 3. ZA promotes vacuolar degradation of Tat2p. (A and B) Tat2p localization in cells grown under normal conditions (A) or treated with ZA (10 μg/ml) for 3 h (B).
The localization of HA2-Tat2 protein of the-wild type strain (SCU7) harboring plasmid pHA2-TAT2 (pSCU301) was observed by indirect immunofluorescence. (A)
Cy3-stained Tat2p (red), Alexia 488-stained Pep12 (green) and DAPI-stained DNA (blue) signals were observed in cells. Nomarski images (DIC) were also recorded.
(B) Alexia 488-stained HA2-Tat2 (green), Cy3-stained alkaline phosphatase (ALP; red) and DAPI-stained DNA (blue) signals were observed in cells. (C) The ZA-
mediated Tat2p decrease was abolished by disruption of PEP4. pep4 (SCU645) cells harboring plasmid pHA2-TAT2 (pSCU301) were treated with ZA for 3 h and
Western blot analysis was done as described in Fig. 2B. (D) Vacuolar localization of Tat2p after ZA treatment in the pep4 mutant. pep4 (SCU645) cells harboring
plasmid pHA2-TAT2 (pSCU301) were treated with ZA for 3 h and Tat2p (red) and DAPI (blue) signals were observed. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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was stimulated in the erg6 mutant when the concentration of
tryptophan in the culture medium was low [2].
Because ergosterol is required for endocytosis [16,25], it is
unlikely that the route from the plasma membrane to the
vacuole is stimulated by ergosterol depletion. The ZA-
induced decrease in Tat2p was still found in endocytosis-
defective end4 mutants (Fig. 5A). This is probably because
Tat2p is predominantly localized in late endosomes, not the
plasma membrane (Fig. 3A) [1,2], in a sharp contrast to Tat2
(5KR)p (Fig. 4A). It is possible the massive degradation of
Tat2p caused by ZA reflects vacuolar degradation of late
endosomal Tat2p. This notion seems to be consistent with thefact that ZA reduces tryptophan uptake activity only by about
half, despite the marked decrease in the cellular Tat2p level.
The decrease in tryptophan uptake activity after ZA treatment
suggests that Tat2p localized on the plasma membrane was
decreased. It is probable that Tat2p sorting from early
endosomes to late endosomes, but not to plasma membranes,
is stimulated by ZA.
To assess the routes of vacuolar degradation of Tat2p, we
examined the effect of deletion of VPS45 on the ZA-mediated
Tat2p degradation. Vps45p (VPS for vacuolar protein sorting) is
necessary for the delivery of vacuolar proteins from the trans-
Golgi network to the pre-vacuolar compartment (PVC), but is
not required for the delivery of endocytosed proteins to the
Fig. 4. Ubiquitination-dependent vacuolar missorting of Tat2p in ZA-treated cells. (A) Tat2(5KR) prevents vacuolar targeting of Tat2p in ZA-treated cells. ZA-treated
wild-type cells harboring plasmid pHA2-TAT2(5KR) (pSCU425) were treated with ZA for 3 h as described in Fig. 3D. The localization of HA2-Tat2(5KR) was
observed by indirect immunofluorescence. Cells not treated with ZA were used as the control (Cont). (B) Tat2(5KR) (lanes 4–6) and rsp5-1 (lanes 7–9) mutations
suppress the ZA-induced Tat2p degradation. ZA-treated cells harboring plasmid pHA2-TAT2 or pHA2-TAT2(5KR) were used for Western blotting. ZA treatment was
done as described in Fig. 2B. Cells were treated with rapamycin (1 h) or ZA (3 h). Cont, non-treated control; Rap, rapamycin-treated cells. The rsp5-1 cells (SCU649)
were transferred to 37 °C (restrictive temperature) before drug treatments. PGK (3-phosphoglycerate kinase) was used as the loading control.
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suppressed the rapamycin-induced Tat2p degradation [1].
However, the degradation occurred to a similar degree even in
the vps45-deleted mutant in our cell background (Fig. 5B
versus Fig. 2C). It is possible that the different genetic
backgrounds of the cells account for these different results.
Deletion of VPS45 also failed to suppress the ZA-induced Tat2p
degradation (Fig. 5B). This suggests that the ZA-promoted
vacuolar degradation of Tat2p is independent of Vps45p.
The dynamin-related GTPase Vps1p is required for vacuolar
sorting from the trans-Golgi to late endosomes [27,28]. Plasma
membrane targeting of Tat2p, which is compromised by high
tryptophan and erg6 mutation, is ameliorated by the vps1
disruption, although there is no reported information about
cellular Tat2p protein levels [2]. PEP12/VPS6 encodes the
syntaxin homolog (t-SNARE) Pep12p involved in Golgi-to-
vacuole transport [29]. Deletion of PEP12 partially suppressed
the rapamycin-mediated Tat2p degradation [1] and alleviated
plasma membrane distribution of Tat2 in the erg6 mutant [2].
However, in our case, the deletion of VPS1 and PEP12 failed to
abrogate the rapamycin- and ZA-induced Tat2p degradation (Fig.
5C). Thus, ZA-induced Tat2p degradation is not dependent on
Vps1p and Pep12p, at least in our cell background, although the
Tat2p distribution in these mutants was not the same as that in the
wild-type strain (see below).Three types of endosome have been characterized: the
early/recycling endosome, PVC, and multivesicular body
(MVB)/late endosome. MVBs/late endosomes are larger,
contain internal vesicles, and are often adjacent to the vacuole.
Some vacuolar membrane proteins and internalized surface
proteins are sorted into internal vesicles during transport
through endosomes in a process known as MVB sorting and
are ultimately delivered to the vacuole lumen [30]. Vps27p is
required for MVB formation and has been proposed to be an
endosomal ubiquitin-sorting receptor [31–34]. Deletion of
VPS27 cancels Tat2p vacuolar degradation by rapamycin, high
tryptophan and high pressure [1–3]. Although deletion of
VPS27 partially suppressed the rapamycin-induced Tat2p
degradation, it could not suppress the ZA-induced Tat2p
degradation (Fig. 5C). This suggests that another pathway than
that involving Vps27p for vacuolar sorting of Tat2p might be
activated in the ZA-treated cells. Considering all these facts, it
is likely that ZA may induce Golgi-to-vacuole targeting of
Tat2p via an aberrant pathway. Thus, we found no obvious
suppression of the ZA-induced Tat2p decrease in several
mutant cells used here, but it is possible that there are
differences of kinetics between the mutants at earlier time
points after drug addition.
A relatively large single signal or a few signals of Tat2p in
the cell were found in the vps1, vps27 and vps45 cells (Figs. 6
Fig. 5. Effects of deletions of VPS genes on ZA-mediated Tat2p degradation. (A–C) Mutant strains end4 (SCU620), vps45 (SCU757), vps1 (SCU718), vps27
(SCU874) and pep12 (SCU755) harboring plasmid pHA2-TAT2p (pSCU301) were treated with rapamycin (1 h) and ZA (3 h). Tat2p (HA-Tat2p) was detected by
Western blot analysis as described in Fig. 4B.
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localization of Tat2p. These signals were co-localized with
Pep12p. It was previously shown that Pep12p is missorted in
vsp1, vps27 and vps45 cells [35–37]. In contrast, punctateFig. 6. Tat2p distribution in vps27 and vps45. Mutant strains vps27 (SCU874) and v
ZA for 3 h. The localization of Tat2p was observed by indirect immunofluorescencsignals of Tat2p were observed in the pep12, even after ZA
treatment (Fig. 7B). It has been reported that deletions of VSP1,
VPS27 and PEP12 promote plasma membrane localization of
green fluorescent protein (GFP)-tagged Tat2p (Tat2p-GFP) [2].ps45 (SCU757) harboring plasmid pHA2-TAT2p (pSCU301) were treated with
e as described in Fig. 3A.
Fig. 8. Model for Tat2p sorting in ZA-treated cells. See the text for details.
Fig. 7. Tat2p distribution in vps1 and pep12. Mutant strains vps1 (SCU718) (A) and pep12 (SCU755) (B) harboring plasmid pHA2-TAT2p (pSCU301) were treated
with ZA for 3 h. The localization of Tat2p was observed by indirect immunofluorescence as described in Fig. 3A.
1688 K. Daicho et al. / Biochimica et Biophysica Acta 1768 (2007) 1681–1690Tat2p-GFP complemented the growth defects of the tat2Δ
under low tryptophan conditions, like HA-tagged Tat2p [2].
However, this only suggests that Tat2p-GFP can be localized on
the plasma membrane regardless of the intracellular distribution
of Tat2p. Indeed, the distribution of Tat2p-GFP was not the
same as that of Tat2p-HA [2]. It is likely that the difference of
tags of Tat2p may have resulted in the difference of the effects
of the deletions of vps1, vps27 and pep12. It may be useful to
analyze endogenous non-tagged Tat2p to exclude effects of
tags.
3.5. A model of ZA effect on Tat2p sorting
We showed herein that the SQS inhibitor ZA evoked massive
vacuolar degradation of Tat2p. This feature is in contrast to that
seen in the erg6 mutants. Tat2p is predominantly distributed in
late endosomes [2] (this study). Therefore, the ZA-induced
Tat2p degradation indicates that ZA, but not the erg6 deletion,
promotes late endosomal Tat2p degradation (Fig. 8). Further-
more, the fact that ZA represses tryptophan uptake (Fig. 2D)
suggests that ZA inhibits the sorting of Tat2p from the early
endosome to the plasma membrane (Fig. 8), like deletion of
ERG6. This plasma membrane sorting is accelerated byinhibition of Rsp5p-mediated ubiquitination of Tat2p even in
the presence of ZA, suggesting that Rsp5p-mediated ubiquiti-
nation of Tat2p may inhibit the plasma membrane sorting of
Tat2p (Fig. 8).
Cholesterol (ergosterol) and sphingolipids are thought to-
gether to form tightly packed lipid microdomains, called “lipid
1689K. Daicho et al. / Biochimica et Biophysica Acta 1768 (2007) 1681–1690rafts”. Lipid rafts are critical for intracellular protein sorting
[38–42]. Tat2p is also associated with lipid rafts under low, but
not high, tryptophan conditions [2,3]. It is likely that zymosterol
(see Fig. 1)-containing lipid rafts in the erg6 mutants stimulate
the sorting of Tat2p from early to late endosomes, but not from
late endosomes to vacuoles. In contrast, the lack of sterol, unlike
zymosterol, in the ZA-treated cells probably promotes both
sorting pathways.
3.6. Concluding remarks
The ZA-induced degradation of Tat2p was dependent on the
ubiquitination of Tat2p, but may not occur via normal vacuolar
sorting pathways. In the case of ZA-mediated ergosterol
depletion, Tat2p may be the Achilles' heel of growth, as it is
in the case of high pressure [5]. Nutrient uptake is specifically
impeded in ergosterol-depleted cells. It is plausible that there is a
physiological system that regulates the sorting of nutrient
transporters by altering sterol synthesis. In support of this notion,
we have found that novel TOR-controlled transcriptional
regulators which are needed for full expression of ERG genes
preferentially control the Golgi-to-plasma membrane sorting of
Tat2p (our unpublished data). We suspect that TOR regulates
Tat2p sorting via these novel factors and are now investigating
this. This control seems to be different from the TOR-regulated
Tat2p sorting via protein kinase Npr1p proposed in a previous
study [18]. The highly conserved membrane trafficking system
implies that similar regulatory systems may exist in other
organisms, including humans. Furthermore, this study suggests
that high cholesterol may guarantee high nutrient import into
cells, and that drugs used to control cholesterol levels could
specifically regulate cellular nutrient import in humans.
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